Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial
Under a Creative Commons license
open archive
Key words
clinical research/practice
lung transplantation/pulmonology
pharmacology
immunosuppression/immune modulation
clinical trial
immunosuppressant
calcineurin inhibitor: cyclosporine A (CsA)
antiproliferative agent: mycophenolate mofetil (MMF)
mechanistic target of rapamycin (mTOR)
bronchiolitis obliterans (BOS)
Abbreviations
AR
acute rejection
BOS
bronchiolitis obliterans syndrome
CF
cystic fibrosis
CI
confidence interval
CMV
cytomegalovirus
COPD
chronic obstructive pulmonary disease
CsA
cyclosporine A
DLTx
double-long transplantation
GFR
glomerular filtration rate
HUS
hemolytic–uremic syndrome
ICU
intensive care unit
IPF
idiopathic pulmonary fibrosis
ITT
intention to treat
LTx
lung transplantation
MMF
mycophenolate mofetil
mTOR
mammalian target of rapamycin
Re-LTx
recurrent lung transplantation
SLTx
single-lung transplantation
TMA
thrombotic microangiopathy
Cited by (0)
Copyright © 2016 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.